<?xml version="1.0" encoding="UTF-8"?>
<p id="par0095">During the present COVID-19 pandemic, the use of Tocilizumab as a therapeutic agent was proposed. Tocilizumab is a humanized anti-IL-6 receptor IgG1 monoclonal antibody used for the treatment of rheumatoid arthritis and other chronic inflammatory diseases [
 <xref rid="bib0070" ref-type="bibr">14</xref>]. By blocking the IL-6-receptor interaction, Tocilizumab inhibits the IL-6-mediated signal transduction. Although clinical data on the use of Tocilizumab in COVID-19 patients derive from small series, some authors recommend its use in critically ill COVID-19 patients with significantly elevated IL-6 levels [
 <xref rid="bib0070" ref-type="bibr">14</xref>].
</p>
